Monalizumab

Monalizumab and IPH5201 developed in collaboration with AstraZeneca advanced into Phase 3 and 2 clinical trials in lung cancer, triggering $55M in milestone payments Second preclinical asset based on...

Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on multispecific antibodies: ANKET for antigen-specific activation of NK...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announced that a planned futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca...

First patient dosed in monalizumab Phase 3 lung cancer trial, PACIFIC-9 sponsored by AstraZeneca, which triggered a $50 million milestone payment extending Company cash runway into 2024 Monalizumab...

First patient dosed in Phase 3 trial, PACIFIC-9, evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable, Stage III non-small cell lung cancer Milestone...

Monalizumab progressing to Phase 3 PACIFIC-9 lung cancer clinical trial in partnership with AstraZeneca First CD123 tri-specific ANKET TM starts Phase 1 study by Sanofi Lacutamab encouraging MF data...

First chemo-free triplet shows preliminary activity and an acceptable safety profile with low rate of discontinuation Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company...

Innate to present new Phase 2 data on the combination of monalizumab, cetuximab and durvalumab in head and neck cancer in an oral presentation ANKET TM to be highlighted in ESMO IO educational session...

Monalizumab in combination with durvalumab significantly delayed disease progression in AstraZeneca’s randomized Phase 2 COAST study in unresectable, Stage III NSCLC, advancing to Phase 3 Pre-clinical...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial...